JF
VERV

Jump Financial’s Verve Therapeutics VERV Stock Holding History

Jump Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-147,819
Closed -$834K – 2048
2024
Q4 		$834K Buy
147,819
+30,661
+26% +$173K 0.02% 831
2024
Q3 		$567K Buy
117,158
+13,167
+13% +$76.5K 0.01% 1046
2024
Q2 		$507K Buy
+103,991
New +$654K 0.01% 1125
2023
Q4 		– Sell
-26,913
Closed -$357K – 2287
2023
Q3 		$357K Buy
+26,913
New +$433K 0.01% 1210
2023
Q1 		– Sell
-37,794
Closed -$731K – 2090
2022
Q4 		$731K Buy
+37,794
New +$1M 0.04% 620
2022
Q3 		– Sell
-37,700
Closed -$576K – 1995
2022
Q2 		$576K Buy
+37,700
New +$584K 0.02% 788

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jump Financial's VERV Position: Q1 2025 in Review

Jump Financial sold out of Verve Therapeutics (VERV) in Q1 2025, closing a stake of 147,819 shares — an estimated $834K sold.

Jump Financial first reported a position in VERV in Q2 2022 and held it in 6 quarters. The position peaked at $834K in Q4 2024. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Jump Financial reported no remaining Verve Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jump Financial sold 147,819 Verve Therapeutics shares in Q1 2025, an estimated $834K.
  • Jump Financial first reported a position in Verve Therapeutics in Q2 2022 and held it in 6 quarters.
  • Jump Financial's Verve Therapeutics position peaked at $834K in Q4 2024.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Jump Financial's 13F filing for Q1 2025, filed 14 May 2025.